- Home
- NCTY vs MAIA Comparison
NCTY vs MAIA Comparison
Compare NCTY & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCTY | MAIA |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.8M | 89.7M |
| IPO Year | 2004 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NCTY | MAIA |
|---|---|---|
| Price | $5.44 | $1.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.8K | ★ 1.1M |
| Earning Date | 03-27-2015 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.00 | $0.87 |
| 52 Week High | $15.98 | $3.19 |
Technical Indicators
Market Signals| Indicator | NCTY | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 43.98 | 31.80 |
| Support Level | $5.02 | $1.26 |
| Resistance Level | $7.22 | $1.74 |
| Average True Range (ATR) | 0.55 | 0.09 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 15.93 | 3.28 |
Price Performance
Historical ComparisonAbout NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.